Literature DB >> 22678511

Kynurenines in the mammalian brain: when physiology meets pathology.

Robert Schwarcz1, John P Bruno, Paul J Muchowski, Hui-Qiu Wu.   

Abstract

The essential amino acid tryptophan is not only a precursor of serotonin but is also degraded to several other neuroactive compounds, including kynurenic acid, 3-hydroxykynurenine and quinolinic acid. The synthesis of these metabolites is regulated by an enzymatic cascade, known as the kynurenine pathway, that is tightly controlled by the immune system. Dysregulation of this pathway, resulting in hyper-or hypofunction of active metabolites, is associated with neurodegenerative and other neurological disorders, as well as with psychiatric diseases such as depression and schizophrenia. With recently developed pharmacological agents, it is now possible to restore metabolic equilibrium and envisage novel therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678511      PMCID: PMC3681811          DOI: 10.1038/nrn3257

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  192 in total

Review 1.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor.

Authors:  Roberto Pellicciari; Rosa C Rizzo; Gabriele Costantino; Maura Marinozzi; Laura Amori; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  ChemMedChem       Date:  2006-05       Impact factor: 3.466

Review 3.  Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.

Authors:  S R Thomas; R Stocker
Journal:  Redox Rep       Date:  1999       Impact factor: 4.412

4.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.

Authors:  Arash Rassoulpour; Hui-Qiu Wu; Sergi Ferre; Robert Schwarcz
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

5.  On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress.

Authors:  R Lugo-Huitrón; T Blanco-Ayala; P Ugalde-Muñiz; P Carrillo-Mora; J Pedraza-Chaverrí; D Silva-Adaya; P D Maldonado; I Torres; E Pinzón; E Ortiz-Islas; T López; E García; B Pineda; M Torres-Ramos; A Santamaría; V Pérez-De La Cruz
Journal:  Neurotoxicol Teratol       Date:  2011-07-13       Impact factor: 3.763

6.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

7.  Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.

Authors:  P Guidetti; P H Reddy; D A Tagle; R Schwarcz
Journal:  Neurosci Lett       Date:  2000-04-14       Impact factor: 3.046

8.  Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis.

Authors:  Klas R Linderholm; Alexandra Andersson; Sara Olsson; Elin Olsson; Ralph Snodgrass; Göran Engberg; Sophie Erhardt
Journal:  Neuropharmacology       Date:  2007-09-20       Impact factor: 5.250

9.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 10.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

View more
  462 in total

1.  Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.

Authors:  Paul B Larkin; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Hiroshi Funakoshi; Toshikazu Nakamura; Robert Schwarcz; Paul J Muchowski
Journal:  Biochim Biophys Acta       Date:  2016-07-05

2.  Tryptophan catabolism and vitamin B-6 status are affected by gender and lifestyle factors in healthy young adults.

Authors:  Oana M Deac; James L Mills; Barry Shane; Øivind Midttun; Per M Ueland; John T Brosnan; Margaret E Brosnan; Eamon Laird; Eileen R Gibney; Ruzong Fan; Yifan Wang; Lawrence C Brody; Anne M Molloy
Journal:  J Nutr       Date:  2015-02-18       Impact factor: 4.798

3.  Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD.

Authors:  Ludovic Belle; Vivian Zhou; Kara L Stuhr; Margaret Beatka; Emily M Siebers; Jennifer M Knight; Michael W Lawlor; Casey Weaver; Misato Hashizume; Cecilia J Hillard; William R Drobyski
Journal:  JCI Insight       Date:  2017-07-20

4.  Exposure to elevated embryonic kynurenine in rats: Sex-dependent learning and memory impairments in adult offspring.

Authors:  Silas A Buck; Annalisa M Baratta; Ana Pocivavsek
Journal:  Neurobiol Learn Mem       Date:  2020-07-30       Impact factor: 2.877

5.  Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; Francesca M Notarangelo; S Andrea Wijtenburg; Marian A R Thomas; Ana Pocivavsek; Aaron Jones; Krista Wisner; Peter Kochunov; Robert Schwarcz; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2018-04-18       Impact factor: 7.853

6.  In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning.

Authors:  Laura Formentini; Marta P Pereira; Laura Sánchez-Cenizo; Fulvio Santacatterina; José J Lucas; Carmen Navarro; Alberto Martínez-Serrano; José M Cuezva
Journal:  EMBO J       Date:  2014-02-12       Impact factor: 11.598

7.  Inhibition of hypoxia-associated response and kynurenine production in response to hyperbaric oxygen as mechanisms involved in protection against experimental cerebral malaria.

Authors:  Marcele F Bastos; Ana Carolina A V Kayano; João Luiz Silva-Filho; João Conrado K Dos-Santos; Carla Judice; Yara C Blanco; Nathaniel Shryock; Michelle K Sercundes; Luana S Ortolan; Carolina Francelin; Juliana A Leite; Rafaella Oliveira; Rosa M Elias; Niels O S Câmara; Stefanie C P Lopes; Letusa Albrecht; Alessandro S Farias; Cristina P Vicente; Claudio C Werneck; Selma Giorgio; Liana Verinaud; Sabrina Epiphanio; Claudio R F Marinho; Pritesh Lalwani; Rogerio Amino; Julio Aliberti; Fabio T M Costa
Journal:  FASEB J       Date:  2018-03-20       Impact factor: 5.191

8.  Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.

Authors:  Jonathan Savitz; Robert Dantzer; Brent E Wurfel; Teresa A Victor; Bart N Ford; Jerzy Bodurka; P S F Bellgowan; T Kent Teague; Wayne C Drevets
Journal:  Psychoneuroendocrinology       Date:  2014-11-24       Impact factor: 4.905

9.  The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.

Authors:  Hannah F Iaccarino; Raymond F Suckow; Shan Xie; David J Bucci
Journal:  Schizophr Res       Date:  2013-09-30       Impact factor: 4.939

10.  Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.

Authors:  Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.